Syringin – 25 mg

Brand:
Cayman
CAS:
118-34-3
Storage:
-20
UN-No:
Non-Hazardous - /

Syringin is a phenylpropanoid glycoside first isolated from A. senticosus that enhances acetylcholine release in pancreatic cells leading to an increase in insulin release through the muscarinic M3 receptor.{34650,34648} Syringin dose-dependently (50, 75, and 100 µg/kg, i.v.) decreases plasma glucose levels and increases insulin-like immunoreactivity and C-peptide in rats, and these effects last at least 60 minutes. In a rat model of type 1 diabetes, it decreases plasma glucose and increases β-endorphin release from the adrenal medulla.{34649} Syringin increases autophagy through AMP-activated protein kinase α (AMPKα) activation concomitant with preventing the progression of cardiac hypertrophy in mice following aortic banding.{34647} It also has immunomodulatory effects, likely due to its metabolite sinapyl alcohol.{34646}  

 

Out of stock

SKU: 22387 - Category:

Description

A modulator of acetylcholine release; dose-dependently (50, 75, and 100 µg/kg, i.v.) decreases plasma glucose levels and increases insulin-like immunoreactivity and C-peptide in rats; increases β-endorphin; increases autophagy through AMPKα activation preventing cardiac hypertrophy progression


Formal name: 4-[(1E)-3-hydroxy-1-propen-1-yl]-2,6-dimethoxyphenyl-β-D-glucopyranoside

Synonyms:  Eleutheroside B|NSC 287441

Molecular weight: 372.4

CAS: 118-34-3

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Kinase Inhibitors|CaMKs||Product Type|Biochemicals|Natural Products|Glycosides||Product Type|Biochemicals|Small Molecule Inhibitors|Kinases||Research Area|Cardiovascular System|Heart|Myocardial Hypertrophy||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Diabetes||Research Area|Immunology & Inflammation